## **SENATE BILL 723**

J3 (8lr2240)

## ENROLLED BILL

—Finance/Health and Government Operations—

Introduced by Senators Klausmeier, Della, and Pugh

Read and Examined by Proofreaders: Proofreader. Proofreader. Sealed with the Great Seal and presented to the Governor, for his approval this \_\_\_\_\_ day of \_\_\_\_\_ at \_\_\_\_ o'clock, \_\_\_\_M. President. CHAPTER AN ACT concerning Pharmacy Benefits Managers - Prescription Drug Substitution Therapeutic **Interchanges** FOR the purpose of prohibiting a pharmacy benefits manager from substituting one prescription drug for the drug originally prescribed or its agent from requesting a therapeutic interchange unless certain conditions are met; requiring a pharmacy benefits manager to disclose certain information to a purchaser if a drug substitution is made; requiring a pharmacy benefits manager or its agent to obtain a certain authorization to make a drug substitution therapeutic interchange and to make certain disclosures to a prescriber; previding for certain exceptions; prohibiting a pharmacy benefits manager from substituting a drug for a currently prescribed drug unless the pharmacy benefits manager provides a beneficiary or the beneficiary's representative with certain information requiring a pharmacy benefits manager or its agent to disclose certain information to a beneficiary and include a certain insert and a certain

## EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

1

2

3

4

5

6

7

8

9 10

11

12

13 14

15

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.

Italics indicate opposite chamber/conference committee amendments.



1 2 3 4 5 6 7 8 9	telephone number with the prescription drug dispensed; requiring a pharmacy benefits manager or its agent to cancel and reverse a therapeutic interchange under certain circumstances; requiring a pharmacy benefits manager or its agent to take certain actions if a therapeutic interchange is reversed; requiring a pharmacy benefits manager to maintain a certain toll–free telephone number; requiring certain disclosures to comply with certain privacy standards; requiring a pharmacy benefits manager to establish certain policies and procedures; making certain provisions applicable to health maintenance organizations; providing certain penalties; defining certain terms; and generally relating to regulation of pharmacy benefits managers.
11 12 13 14 15 16	BY adding to Article – Insurance Section 15–1601 <u>and 15–1602</u> to be under the new subtitle "Subtitle 16. Pharmacy Benefits Managers" Annotated Code of Maryland (2006 Replacement Volume and 2007 Supplement)
17 18 19 20 21	BY adding to  Article – Health – General Section 19–706(ppp) Annotated Code of Maryland (2005 Replacement Volume and 2007 Supplement)
22 23	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:
24	Article - Insurance
25	SUBTITLE 16. PHARMACY BENEFITS MANAGERS.
26	<del>15-1601.</del>
27 28	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.
29 30 31	(2) "BENEFICIARY" MEANS AN INDIVIDUAL ON WHOSE BEHALF A PURCHASER ENTERS INTO AN AGREEMENT WITH A PHARMACY BENEFITS MANAGER.
32 33 34	(3) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS THE ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG BENEFITS.
35 36	(II) "PHARMACY BENEFITS MANAGEMENT SERVICES"  INCLUDES:

1	1. PROCUREMENT OF PRESCRIPTION DRUGS AT A
2	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE;
3	2. PROCESSING OF PRESCRIPTION DRUG CLAIMS;
4	3. ADMINISTRATION OF PAYMENTS RELATED TO
5	PRESCRIPTION DRUG CLAIMS; AND
6	4. NEGOTIATING OR ENTERING INTO CONTRACTUAL
7	ARRANGEMENTS WITH PHARMACY PROVIDERS.
0	(A) ((P
8	(4) "PHARMACY BENEFITS MANAGER" MEANS A PERSON THAT
9	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
10	(F) (I) (IDVDGVAGDD? AFDANG A DEDGON MVAG DAVEDDG INMO AN
10	(5) (1) "PURCHASER" MEANS A PERSON THAT ENTERS INTO AN
11	AGREEMENT WITH A PHARMACY BENEFITS MANAGER FOR THE PROVISION OF
12	PHARMACY BENEFITS MANAGEMENT SERVICES.
10	(T) (Dran dra 1 dran 11 mag arran Con 1 mag
13	(II) "PURCHASER" INCLUDES THE STATE.
1.4	(D) THE PROVICIONS OF THIS SECTION DO NOT APPLY TO A MANAGED
14	(B) THE PROVISIONS OF THIS SECTION DO NOT APPLY TO A MANAGED
15 16	CARE ORGANIZATION AUTHORIZED BY TITLE 15, SUBTITLE 1 OF THE
16	HEALTH - GENERAL ARTICLE.
17	
18	(C) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
	PRESCRIPTION DRUG FOR THE CURRENTLY PRESCRIBED PRESCRIPTION DRUG
19	<del>UNLESS:</del>
20	(1) THE CHECKER PROPERTY OF THE POPULATION OF A CONTRACTOR
21	(1) THE SUBSTITUTION IS MADE FOR MEDICAL REASONS THAT
41	BENEFIT THE BENEFICIARY; OR
22	(2) THE SUBSTITUTION RESULTS IN FINANCIAL SAVINGS AND
23	(
۷٥	BENEFITS TO THE PURCHASER.
24	(D) IF A PRESCRIPTION DRUG SUBSTITUTION IS MADE UNDER THIS
2 <del>5</del>	SECTION, THE PHARMACY BENEFITS MANAGER SHALL DISCLOSE TO THE
26	PURCHASER ANY BENEFIT OR PAYMENT:
40	TOROTHOLINATE DETERMENT OR FAIRMENTS
27	(1) RELATED TO THE SUBSTITUTION; AND
41	(1) RELATED TO THE SUBSTITUTION, MAD
28	(2) RECEIVED IN ANY FORM BY THE PHARMACY BENEFITS
29	MANAGER FROM A PHARMACEUTICAL MANUFACTURER OR OTHER PERSON.
	The trouble resident in the state of the sta

1	(E) EXCEPT AS PROVIDED IN SUBSECTIONS (G) AND (H) OF THE
2	SECTION, A PHARMACY BENEFITS MANAGER SHALL:
3	(1) OBTAIN AUTHORIZATION FROM A PRESCRIBER T
4	SUBSTITUTE ANOTHER PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBE
5	PRESCRIPTION DRUG; AND
0	
6	(2) DISCLOSE TO THE PRESCRIBER:
7	(I) THE COST SAVINGS FOR THE PURCHASER, IF ANY, THA
8	RESULT FROM THE DRUG SUBSTITUTION;
9	(II) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHE
10	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN TH
11	SUBSTITUTE DRUG;
12	(III) THE EXISTENCE OF ADDITIONAL PAYMENTS RECEIVE
13	BY THE PHARMACY BENEFITS MANAGER THAT ARE NOT REFLECTED IN THE
14	COST SAVINGS TO THE PURCHASER;
15	(DI) THE CIRCLEMOTANCES IN ANY UNDER WHICH TH
16	(IV) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
10	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
17	(V) THE CIRCUMSTANCES, IF ANY, AND EXTENT TO WHIC
18	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL B
19	COMPENSATED; AND
20	(VI) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON
21	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS.
	, and the second se
22	(F) IF AUTHORIZATION IS GIVEN VERBALLY, A PHARMACY BENEFIT
23	MANAGER SHALL RECORD THE NAME AND TITLE OF THE PRESCRIBE
24	AUTHORIZING THE PRESCRIPTION DRUG SUBSTITUTION.
25	(G) SUBSECTION (E) OF THIS SECTION DOES NOT APPLY IF THE
26	SUBSTITUTION IS FROM A BRAND NAME DRUG TO A GENERIC DRUG, AND TH
27	SUBSTITUTION IS MADE IN ACCORDANCE WITH § 12-504 OF THE HEALT
28	OCCUPATIONS ARTICLE.
29	(H) SUBSECTION (E)(2) OF THIS SECTION DOES NOT APPLY IF:
	( ,
30	(1) THE CURRENTLY PRESCRIBED DRUG IS NO LONGE
31	AVAILABLE IN THE MARKET; OR

1	(2) THE SUBSTITUTION IS REQUIRED FOR COVERAGE REASONS
2	BECAUSE THE PRESCRIBED DRUG IS NOT COVERED BY THE BENEFICIARY'S
3	FORMULARY OR PLAN.
4	(I) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
5	PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED PRESCRIPTION DRUG
6	UNLESS THE PHARMACY BENEFITS MANAGER PROVIDES THE BENEFICIARY OR
7	THE BENEFICIARY'S REPRESENTATIVE THE FOLLOWING:
8	(1) UNLESS THE SUBSTITUTION WAS EXEMPTED UNDER
9	SUBSECTION (G) OF THIS SECTION, A NOTHFICATION THAT:
10	(I) THE PHARMACY BENEFITS MANAGER REQUESTED A
11	DRUG SUBSTITUTION BY CONTACTING THE BENEFICIARY'S PRESCRIBER; AND
12	(II) THE PRESCRIBER APPROVED THE DRUG SUBSTITUTION;
13	(2) THE NAMES OF THE PROPOSED DRUG SUBSTITUTION AND THE
14	CURRENTLY PRESCRIBED DRUG;
15	(3) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
16	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
17	SUBSTITUTE DRUG;
18	(4) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
19	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS;
20	(5) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
21	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
22	(6) THE CIRCUMSTANCES, IF ANY, AND THE EXTENT TO WHICH
23	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
24	COMPENSATED;
25	(7) A NOTIFICATION THAT THE BENEFICIARY MAY DECLINE THE
26	DRUG SUBSTITUTION IF THE CURRENTLY PRESCRIBED DRUG REMAINS ON THE
27	BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY ANY
28	DIFFERENCE IN THE COPAYMENT AMOUNT; AND
29	(8) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE WITH
30	THE PHARMACY BENEFITS MANAGER.
31	(J) (1) A PHARMACY BENEFITS MANAGER SHALL CANCEL AND
32	REVERSE A PRESCRIPTION DRUG SUBSTITUTION ON WRITTEN OR VERBAL

1	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
2	BENEFICIARY'S REPRESENTATIVE.
3	(2) If a prescriber, the beneficiary, or the beneficiary's
$\frac{3}{4}$	REPRESENTATIVE CANCELS AND REVERSES A DRUG SUBSTITUTION, THE
5	PHARMACY BENEFITS MANAGER SHALL:
0	THAT WAS TO SHOULD THE STATE OF
6	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE
7	CURRENTLY PRESCRIBED DRUG;
8	(H) CHARGE THE BENEFICIARY ONLY ONE COPAYMENT; AND
9	(III) IF A BENEFICIARY WILL EXHAUST THE SUPPLY OF THE
10	CURRENTLY PRESCRIBED DRUG BEFORE A REPLACEMENT SHIPMENT WILL
11	ARRIVE TO THE BENEFICIARY, ARRANGE FOR DISPENSING OF AN APPROPRIATE
12	QUANTITY OF REPLACEMENT DRUGS AT A RETAIL OR INSTITUTIONAL
13	PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
1.1	
14	(3) A PHARMACY BENEFITS MANAGER MAY NOT BE REQUIRED TO
15	CANCEL AND REVERSE A DRUG SUBSTITUTION IF:
16	(I) THE PRESCRIBED DRUG IS NO LONGER ON THE
17	PURCHASER'S FORMULARY; OR
1.	1 OROTHOPH S PORTULARLY, OR
18	(H) A BENEFICIARY IS UNWILLING TO PAY A HIGHER
19	COPAYMENT OR OTHER COST ASSOCIATED WITH THE PRESCRIBED DRUG.
20	(K) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A TOLL-FREE
21	TELEPHONE NUMBER 24 HOURS A DAY, 7 DAYS A WEEK, FOR PRESCRIBERS,
22	PHARMACY PROVIDERS, AND BENEFICIARIES.
23	(L) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
24	WITH THE PRIVACY STANDARDS OF THE FEDERAL HEALTH INSURANCE
25	PORTABILITY AND ACCOUNTABILITY ACT.
26	(M) ON OR BEFORE APRIL 1, 2009, THE COMMISSIONER SHALL ADOPT
$\frac{27}{27}$	REGULATIONS TO IMPLEMENT THIS SECTION.
	TEGELITORS TO BIT DEVILOR THIS SECTION.
28	(N) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT
29	EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
30	(2) In addition to or instead of assessing a civil penalty,
31	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO

	SENATE BILL 129
1	MAKE RESTITUTION TO ANY PERSON WHO HAS SUFFERED FINANCIAL INJURY
2	BECAUSE OF THE VIOLATION OF THIS SECTION.
3	<u>15–1601.</u>
4 5	(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.
6 7	(B) "AGENT" MEANS A PHARMACY, A PHARMACIST, A MAIL ORDER PHARMACY, OR A NONRESIDENT PHARMACY ACTING ON BEHALF OR AT THE
8	DIRECTION OF A PHARMACY BENEFITS MANAGER.
O	DIRECTION OF ATTIAIRMACT DENEFTIS MANAGER.
9	(C) "BENEFICIARY" MEANS AN INDIVIDUAL WHO RECEIVES
10	PRESCRIPTION DRUG COVERAGE OR BENEFITS FROM A PURCHASER.
11	(D) "ERISA" HAS THE MEANING STATED IN § 8–301 OF THIS ARTICLE.
12	(E) "Nonprofit health maintenance organization" has the
13	MEANING STATED IN § 6–121(A) OF THIS ARTICLE.
14	(F) "Nonresident pharmacy" has the meaning stated in § 12–403
15	OF THE HEALTH OCCUPATIONS ARTICLE.
16	(G) "PHARMACIST" HAS THE MEANING STATED IN § 12–101 OF THE
17	HEALTH OCCUPATIONS ARTICLE.
18	(H) "PHARMACY" HAS THE MEANING STATED IN § 12–101 OF THE
19	HEALTH OCCUPATIONS ARTICLE.
20	(I) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS:
21	(I) THE PROCUREMENT OF PRESCRIPTION DRUGS AT A
22	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE TO BENEFICIARIES;
	recounted wife for dist ensation within the state to beneficiaties,
23	(II) THE ADMINISTRATION OR MANAGEMENT OF

26 <u>(III) ANY OF THE FOLLOWING SERVICES PROVIDED WITH</u> 27 <u>REGARD TO THE ADMINISTRATION OF PRESCRIPTION DRUG COVERAGE:</u>

24

25

28

**BENEFICIARIES; AND** 

1. MAIL SERVICE PHARMACY;

PRESCRIPTION DRUG COVERAGE PROVIDED BY A PURCHASER FOR

1	2. CLAIMS PROCESSING, RETAIL NETWORK
<b>2</b>	MANAGEMENT, AND PAYMENT OF CLAIMS TO PHARMACIES FOR PRESCRIPTION
3	DRUGS DISPENSED TO BENEFICIARIES;
4	3. CLINICAL FORMULARY DEVELOPMENT AND
5	MANAGEMENT SERVICES;
0	
6	4. REBATE CONTRACTING AND ADMINISTRATION;
7	5. PATIENT COMPLIANCE, THERAPEUTIC
8	INTERVENTION, AND GENERIC SUBSTITUTION PROGRAMS; OR
9	6. DISEASE MANAGEMENT PROGRAMS.
10	(2) "PHARMACY BENEFITS MANAGEMENT SERVICES" DOES NOT
11	INCLUDE ANY SERVICE PROVIDED BY A NONPROFIT HEALTH MAINTENANCE
12	ORGANIZATION THAT OPERATES AS A GROUP MODEL, PROVIDED THAT THE
13	SERVICE:
1.4	(7)
14	(I) IS PROVIDED SOLELY TO A MEMBER OF THE NONPROFIT
15	HEALTH MAINTENANCE ORGANIZATION; AND
16	(II) IS FURNISHED THROUGH THE INTERNAL PHARMACY
17	OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
18	(J) "PHARMACY BENEFITS MANAGER" MEANS A PERSON THAT
19	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
20	(K) "PHARMACY AND THERAPEUTICS COMMITTEE" MEANS A
21	COMMITTEE ESTABLISHED BY A PHARMACY BENEFITS MANAGER TO:
	COMMITTIBLE ESTIBILISHED BY ITT HERWING PRINTED TO MENTION TO
22	(1) OBJECTIVELY APPRAISE AND EVALUATE PRESCRIPTION
23	DRUGS; AND
24	(2) MAKE RECOMMENDATIONS TO A PURCHASER REGARDING THE
25	SELECTION OF DRUGS FOR THE PURCHASER'S FORMULARY.
26	(L) (1) "PURCHASER" MEANS THE STATE EMPLOYEE AND RETIREE
27	HEALTH AND WELFARE BENEFITS PROGRAM, AN INSURER, A NONPROFIT
28	HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT:
29	(I) PROVIDES PRESCRIPTION DRUG COVERAGE OR
30	BENEFITS IN THE STATE; AND

1	(II) ENTERS INTO AN AGREEMENT WITH A PHARMACY
$\frac{2}{3}$	BENEFITS MANAGER FOR THE PROVISION OF PHARMACY BENEFITS MANAGEMENT SERVICES.
O	MANAGEMENT SERVICES.
4	(2) "PURCHASER" DOES NOT INCLUDE A PERSON THAT PROVIDES
5	PRESCRIPTION DRUG COVERAGE OR BENEFITS THROUGH PLANS SUBJECT TO
6 7	ERISA AND DOES NOT PROVIDE PRESCRIPTION DRUG COVERAGE OR BENEFITS
8	THROUGH INSURANCE, UNLESS THE PERSON IS A MULTIPLE EMPLOYER WELFARE ARRANGEMENT AS DEFINED IN § 514(B)(6)(A)(II) OF ERISA.
O	WEDI'AILE AILIANGEMENT AS DEFINED IN \$ 911(B)(U)(A)(II) OF LILIDIA.
9	(M) (1) "THERAPEUTIC INTERCHANGE" MEANS ANY CHANGE FROM
10	ONE PRESCRIPTION DRUG TO ANOTHER.
11	(2) "THERAPEUTIC INTERCHANGE" DOES NOT INCLUDE:
	(2)IIIEIGH EOITO INTERCIPANCE DOES NOT INCLUDE.
12	(I) A CHANGE INITIATED PURSUANT TO A DRUG
13	UTILIZATION REVIEW;
14	(II) A CHANGE INITIATED FOR PATIENT SAFETY REASONS;
	(II) MEIMIGE INTERFED FORTMENT SHEET REASONS,
15	(III) A CHANGE REQUIRED DUE TO MARKET UNAVAILABILITY
16	OF THE CURRENTLY PRESCRIBED DRUG;
17	(IV) A CHANGE FROM A BRAND NAME DRUG TO A GENERIC
18	DRUG IN ACCORDANCE WITH § 12–504 OF THE HEALTH OCCUPATIONS
19	ARTICLE; OR
20	(7)
20 $21$	(V) A CHANGE REQUIRED FOR COVERAGE REASONS BECAUSE THE ORIGINALLY PRESCRIBED DRUG IS NOT COVERED BY THE
21	BENEFICIARY'S FORMULARY OR PLAN.
	BEN 121 TOTAL ST CHANGE MAY CAN I MAN
23	(N) "THERAPEUTIC INTERCHANGE SOLICITATION" MEANS ANY
24	COMMUNICATION BY A PHARMACY BENEFITS MANAGER FOR THE PURPOSE OF
25	REQUESTING A THERAPEUTIC INTERCHANGE.
26	15–1602.
27	(A) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT REQUEST
28	A THERAPEUTIC INTERCHANGE UNLESS:
29	(1) THE PROPOSED THERAPEUTIC INTERCHANGE IS FOR
30	MEDICAL REASONS THAT BENEFIT THE BENEFICIARY; OR

30

33

**SOLICITATION.** 

	10 SENATE BILL 125
${1 \atop 2}$	(2) THE PROPOSED THERAPEUTIC INTERCHANGE WILL RESULT IN FINANCIAL SAVINGS AND BENEFITS TO THE PURCHASER OR THE BENEFICIARY.
	THURSDAY HOS AND BENEFITS TO THE PERCENCIPAL OR THE BENEFICEART.
3	(B) (1) BEFORE MAKING A THERAPEUTIC INTERCHANGE, A
4	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL OBTAIN AUTHORIZATION
5	FROM A PRESCRIBER OR AN INDIVIDUAL AUTHORIZED BY THE PRESCRIBER.
6	(C) IN ANY THERAPEUTIC INTERCHANGE SOLICITATION, THE
7	FOLLOWING SHALL BE DISCLOSED TO THE PRESCRIBER:
8	(1) THAT A THERAPEUTIC INTERCHANGE IS BEING SOLICITED;
9	(2) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
10	PRESCRIBED DRUG WILL BE COVERED BY THE PURCHASER;
11	(3) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO BE
12	PAID BY THE BENEFICIARY TO OBTAIN THE PROPOSED DRUG;
13	(4) THE CIRCUMSTANCES AND EXTENT TO WHICH HEALTH CARE
14	COSTS RELATED TO THE THERAPEUTIC INTERCHANGE WILL BE COMPENSATED;
15	AND
16	(5) ANY CLINICALLY SIGNIFICANT DIFFERENCES, AS
17	DETERMINED BY A PHARMACY AND THERAPEUTICS COMMITTEE OF THE
18	PHARMACY BENEFITS MANAGER, WITH RESPECT TO EFFICACY, SIDE EFFECTS,
19	AND POTENTIAL IMPACT ON HEALTH AND SAFETY.
90	(D) WHEN GOLIGIPING A THERADELING INTERPOLITANCE EROM A
<ul><li>20</li><li>21</li></ul>	(D) WHEN SOLICITING A THERAPEUTIC INTERCHANGE FROM A PRESCRIBER, A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT MAKE A
22	CLAIM THAT THE THERAPEUTIC INTERCHANGE WILL SAVE THE PURCHASER
23	MONEY UNLESS THE CLAIM CAN BE SUBSTANTIATED.
0.4	
24	(E) IF THE PHARMACY BENEFITS MANAGER OR ITS AGENT RECEIVES
<ul><li>25</li><li>26</li></ul>	PAYMENT FOR MAKING A THERAPEUTIC INTERCHANGE FROM A PHARMACEUTICAL MANUFACTURER OR OTHER PERSON, INCLUDING THE
27	PHARMACY BENEFITS MANAGER, THAT IS NOT REFLECTED IN COST SAVINGS TO
28	THE PURCHASER, THE EXISTENCE OF THE PAYMENT SHALL BE COMMUNICATED
29	TO THE PRESCRIBER AT THE TIME OF THE THERAPEUTIC INTERCHANGE

- 31 <u>(F) IF A THERAPEUTIC INTERCHANGE OCCURS, THE PHARMACY</u> 32 <u>BENEFITS MANAGER OR ITS AGENT SHALL:</u>
  - (1) <u>DISCLOSE TO THE BENEFICIARY, ORALLY OR IN WRITING:</u>

1	(I) THAT THE PHARMACY BENEFITS MANAGER OR ITS
2	AGENT REQUESTED A THERAPEUTIC INTERCHANGE BY CONTACTING THE
3	BENEFICIARY'S PRESCRIBER;
,	
4	(II) THE PRESCRIBER APPROVED THE THERAPEUTIC
5	INTERCHANGE;
6	(III) THE NAMES OF THE ORIGINALLY PRESCRIBED DRUG
7	AND THE DRUG DISPENSED PURSUANT TO THE THERAPEUTIC INTERCHANGE;
•	AND THE DICCODIST ENSEDT CROCKET TO THE THERAI ECTIC INTERCHANCE,
8	(IV) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO
9	BE PAID BY THE BENEFICIARY TO OBTAIN THE DRUG DISPENSED PURSUANT TO
10	THE THERAPEUTIC INTERCHANGE;
11	(V) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
12	PRESCRIBED DRUG WILL BE COVERED;
10	
13	(VI) THE CIRCUMSTANCES UNDER AND THE EXTENT TO
14	WHICH HEALTH CARE COSTS RELATED TO THE THERAPEUTIC INTERCHANGE
15	WILL BE COMPENSATED; AND
16	(VII) THAT THE BENEFICIARY MAY DECLINE THE
17	THERAPEUTIC INTERCHANGE IF THE ORIGINALLY PRESCRIBED DRUG REMAINS
18	ON THE BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY
19	ANY DIFFERENCE IN THE COPAYMENT OR COINSURANCE; AND
20	(2) INCLUDE WITH THE PRESCRIPTION DRUG DISPENSED:
0.1	(-)
21	(I) A PATIENT PACKAGE INSERT ABOUT POTENTIAL SIDE
22	EFFECTS; AND
23	(II) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE
24	WITH THE PHARMACY BENEFITS MANAGER.
	WITH THE THROUGHOUT BELLET ITS MAINTAINE
25	(G) (1) A PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL
26	CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE ON WRITTEN OR VERBAL
27	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
28	BENEFICIARY'S REPRESENTATIVE.
20	(0)
29	(2) If a therapeutic interchange is reversed, the
30	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL:

1	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE
2	ORIGINALLY PRESCRIBED PRESCRIPTION DRUG; AND
	· · · · · · · · · · · · · · · · · · ·
3	(II) CHARGE THE BENEFICIARY NO MORE THAN ONE
4	COPAYMENT.
5	(3) IF THE THERAPEUTIC INTERCHANGE OCCURRED THROUGH A
6	MAIL ORDER PHARMACY AND A BENEFICIARY WILL EXHAUST AN EXISTING
7	SUPPLY OF THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG BEFORE A
8	REPLACEMENT SHIPMENT WILL ARRIVE TO THE BENEFICIARY, THE PHARMACY
9	BENEFITS MANAGER OR ITS AGENT SHALL ARRANGE FOR DISPENSING OF AN
10	APPROPRIATE QUANTITY OF REPLACEMENT PRESCRIPTION DRUGS AT A LOCAL
11	COMMUNITY PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
12	(4) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT BE
13	REQUIRED TO CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE IF A
14	BENEFICIARY IS UNWILLING TO PAY A HIGHER COPAYMENT OR COINSURANCE
15	ASSOCIATED WITH THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG.
16	(H) (1) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A
17	TOLL-FREE TELEPHONE NUMBER MONDAY THROUGH SATURDAY FOR
18	PRESCRIBERS, PHARMACIES, PHARMACISTS, AND BENEFICIARIES TO REQUEST
19	INFORMATION REGARDING A THERAPEUTIC INTERCHANGE.
20	
20	(2) THE TOLL-FREE TELEPHONE NUMBER SHALL BE ACCESSIBLE
21	FROM 8 A.M. UNTIL AT LEAST 8 P.M. EASTERN STANDARD TIME.
22	(I) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
23	WITH THE PRIVACY STANDARDS SET FORTH IN STATE AND FEDERAL LAW.
20	WITH THE PRIVACT STANDARDS SET FORTH IN STATE AND FEDERAL LAW.
24	(J) A PHARMACY BENEFITS MANAGER SHALL ESTABLISH APPROPRIATE
25	POLICIES AND PROCEDURES TO IMPLEMENT THE REQUIREMENTS OF THIS
26	SECTION.
-0	<u>DECITOR</u>
27	(K) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT
28	EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
29	(2) In addition to or instead of assessing a civil penalty,
30	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
31	MAKE RESTITUTION TO ANY PERSON THAT HAS SUFFERED FINANCIAL INJURY
32	BECAUSE OF A VIOLATION OF THIS SECTION.

13 <u>19–706.</u> 1 2 THE PROVISIONS OF TITLE 15, SUBTITLE 16 OF THE INSURANCE (PPP) 3 ARTICLE APPLY TO HEALTH MAINTENANCE ORGANIZATIONS. SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 4 5 October 1, 2008. Approved:

Speaker of the House of Delegates.

President of the Senate.

Governor.